The Public Health Agency of Canada's national Creutzfeldt-Jakob disease dashboard, whose data the agency states are up to date as of June 19, 2026, continues to report more sporadic CJD (sCJD) cases from 2015 onward than in the years before 2015. The agency's own note on the dashboard attributes that increase to the introduction of the end-point quaking-induced conversion (Ep-QuIC) assay by its National Microbiology Laboratory in February 2016, not to a change in how often the disease occurs. The dashboard also reports an increase in age-specific mortality over time in every age group above 50, and cautions that its case-based rates are a proxy for incidence, calculated by the year a case investigation was opened, because dates of symptom onset are difficult to establish in CJD. Rates for 2026 will be revised when updated Statistics Canada population estimates are released.

The counts behind that picture come from the Canadian Creutzfeldt-Jakob Disease Surveillance System (CJDSS), which began prospective national surveillance in 1998. The agency's statistics tables, dated November 30, 2025, list 1,533 definite and probable cases since 1998: 1,421 sporadic, 104 genetic, 6 iatrogenic and 2 variant. Annual sporadic counts ran between 22 and 48 through 1998 to 2009; the table records 68 for 2024. Referrals of suspected cases show the same shape, rising from 98 in 2015 to 117 in 2016 and 155 in 2024, with 162 in 2022, out of 2,967 referrals in total. The agency states that these data are subject to ongoing revision, that cases may be added, updated or removed after reclassification, and that the most recent year is incomplete: 46 sporadic cases were listed for 2025 at the time of that release. Ontario (554) and Quebec (397) account for most cumulative cases; no definite or probable cases have been identified in the Northwest Territories or Nunavut, though their populations are included in national denominators.

Peer-reviewed work from the same agency supports the ascertainment explanation rather than a genuine surge. A retrospective study of Canada-wide cerebrospinal fluid testing from 2016 to 2024, published in the Canadian Journal of Neurological Sciences on May 21, 2025, estimated national CJD incidence at 1.51 cases per million people per year using positive Ep-QuIC results, within the one to two per million range reported internationally. That study found no significant variation between provinces apart from New Brunswick, where 21 of 303 submitted samples were positive, about 2.5 per million per year, which the authors attributed to heightened local testing rather than excess disease. A further report by agency laboratory staff, published in Frontiers in Neurology on December 19, 2025, compared testing periods before, during and after the COVID-19 pandemic and concluded Canadian incidence remained stable. For historical comparison, the agency's own 1998 to 2013 mortality review, published in 2015, counted 662 deaths from definite and probable CJD, 613 of them sporadic.

Canada's figures sit alongside surveillance published elsewhere this year. The Australian National Creutzfeldt-Jakob Disease Registry, reporting to December 31, 2025 in Communicable Diseases Intelligence on July 21, 2026, received 788 domestic cerebrospinal fluid specimens in 2025 and recorded 84 initial case notifications for that year, of which 35 were confirmed as definite or probable prion disease, five were excluded and 44 remained classified as incomplete. A review of Brazilian prion disease surveillance published in Frontiers in Neuroscience on January 29, 2026 argued that the country's health ministry still lacks a database reliable enough to describe the national picture. Read together, the three sets of numbers illustrate how much reported prion disease counts depend on how intensively, and how recently, a country tests.